Table 1.
Relevant demographic, clinical, and pathologic characteristics of all included patients
| Characteristic | All (N=451) | FOLFOX (n=70) | CP (n=239) | No Induction (n=142) | P |
|---|---|---|---|---|---|
| Age, years | 64 (29 to 84) | 65 (41 to 80) | 64 (29 to 84) | 65 (36 to 84) | 0.35 |
| Sex | 0.49 | ||||
| Male | 382 (85) | 56 (80) | 205 (86) | 121 (85) | |
| Female | 69 (15) | 14 (20) | 34 (14) | 21 (15) | |
| Race | 0.51 | ||||
| White | 409 (91) | 63 (90) | 215 (90) | 131 (92) | |
| Black | 3 (0.7) | 0 (0) | 3 (1) | 0 (0) | |
| Asian | 16 (4) | 4 (6) | 6 (3) | 6 (4) | |
| Other | 23 (5) | 3 (4) | 15 (6) | 5 (4) | |
| Smoking status | 0.58 | ||||
| Former/current | 301 (67) | 44 (63) | 158 (66) | 99 (70) | |
| Never | 150 (33) | 26 (37) | 81 (34) | 43 (30) | |
| Baseline grade | >0.9 | ||||
| Well/moderate | 249 (56) | 38 (57) | 132 (55) | 79 (56) | |
| Poor | 196 (44) | 29 (43) | 106 (45) | 61 (44) | |
| cT | 0.47 | ||||
| 1/2 | 55 (12) | 6 (9) | 26 (11) | 23 (16) | |
| 3 | 373 (83) | 59 (87) | 200 (84) | 114 (80) | |
| 4a | 21 (5) | 3 (4) | 13 (5) | 5 (4) | |
| cN | 0.51 | ||||
| N0 | 135 (30) | 22 (31) | 66 (28) | 47 (33) | |
| N+ | 316 (70) | 48 (69) | 173 (72) | 95 (67) | |
| ASA | 0.62 | ||||
| ASA II | 63 (14) | 9 (13) | 37 (15) | 17 (12) | |
| ASA III | 362 (80) | 58 (83) | 185 (77) | 119 (84) | |
| ASA IV | 26 (6) | 3 (4) | 17 (7) | 6 (4) | |
| Esophagectomy type | 0.049 | ||||
| Ivor Lewis | 420 (93) | 65 (93) | 217 (91) | 138 (97) | |
| Other | 31 (7) | 5 (7) | 22 (9) | 4 (3) | |
| LVI | 100 (22) | 7 (10) | 58 (24) | 35 (25) | 0.028 |
| Neural invasion | 105 (23) | 13 (19) | 57 (24) | 35 (25) | 0.59 |
| Pathologic grade | 0.020 | ||||
| Well/moderate | 192 (44) | 25 (39) | 106 (45) | 61 (44) | |
| Poor | 142 (32) | 14 (22) | 83 (35) | 45 (32) | |
| No residual cancer | 103 (24) | 25 (39) | 45 (19) | 33 (24) | |
| ypTNM stage | 0.59 | ||||
| I | 205 (45) | 36 (51) | 104 (44) | 65 (46) | |
| II | 61 (14) | 12 (17) | 30 (13) | 19 (13) | |
| III | 168 (37) | 20 (29) | 97 (41) | 51 (36) | |
| IV | 17 (4) | 2 (3) | 8 (3) | 7 (5) |
Data are no. (%) or median (range). Statistical analysis was performed using the Pearson χ2 test or Fisher’s exact test when any expected cell count was <5 for categorical variables and the Wilcoxon rank-sum test for continuous variables. ASA, American Society of Anesthesiology; CP, carboplatin plus paclitaxel; LVI, lymphovascular invasion; ypTNM stage, pathologic stage of disease after neoadjuvant chemoradiation.